Human Genome Sciences Reports Results of Preclinical Study

Human Genome Sciences has announced the results of a preclinical study comparing the antiviral efficacy of unmodified interferon alpha with three longer-acting modified forms of interferon alpha, including Albuferon.

The results demonstrate that Albuferon (albumin-interferon alpha) exhibits more antiviral activity at clinically achieved serum levels than standard interferon alpha or the modified interferons, Pegasys (peginterferon alfa-2a) and Peg-Intron (peginterferon alfa-2b).